A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma
Latest Information Update: 26 Aug 2026
At a glance
- Drugs Padeliporfin (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
- Focus Adverse reactions
- Sponsors ImPact Biotech; Steba Biotech
Most Recent Events
- 19 Aug 2026 Planned primary completion date changed from 30 May 2026 to 30 Aug 2026.
- 30 May 2026 According to ImPact Biotech media release, data from this trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
- 30 May 2026 Results published in the ImPact Biotech Media Release